Literature DB >> 11417503

The University of California, Irvine experience with tomotherapy using the Peacock system.

M Al-Ghazi1, R Kwon, J Kuo, N Ramsinghani, R Yakoob.   

Abstract

Our institutional experience using the Peacock system for intensity-modulated radiation therapy (IMRT) is summarized. Over 100 patients were treated using this system, which is fitted to a Clinac 600C linac. Both cranial and extracranial lesions have been treated using this modality. Immobilization is achieved either with the Talon system for cranial sites or an Aquaplast cast. Target volumes up to 500 cm3 have been treated. Multiple lesions (up to 3) were treated in one setup. The range of dose/fractionation schemes used was 15 Gy/1 fx (radiosurgical treatment) - 80 Gy/40 fx. Dose validation studies were carried out using film and ion chamber dosimetry in a specially designed phantom. Optimal dose distributions were attainable using inverse treatment planning for IMRT delivery. These were found to encompass the target volumes accurately using dose validation phantom studies. Immobilization methods used were accurate to within 1 mm, as evidenced by daily portal films. IMRT using the Peacock system offers the advantage of delivery of conformal therapy to high doses safely and accurately. This provides the opportunity for dose escalation studies, retreatment of previously treated tumors, as well as treating multiple targets in one setup. The system may be fitted to a conventional linac without major modifications.

Entities:  

Mesh:

Year:  2001        PMID: 11417503     DOI: 10.1016/s0958-3947(00)00061-3

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  2 in total

1.  Quality assurance of TomoDirect treatment plans using I'mRT MatriXX.

Authors:  Cw Kong; Sk Yu; Ky Cheung; H Geng; Yw Ho; Ww Lam; Wk Wong
Journal:  Biomed Imaging Interv J       Date:  2012-04-01

2.  Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme.

Authors:  Clifton D Fuller; Mehee Choi; Britta Forthuber; Samuel J Wang; Nancy Rajagiriyil; Bill J Salter; Martin Fuss
Journal:  Radiat Oncol       Date:  2007-07-14       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.